Global erythropoietin (EPO) Market 2016-2021 Demand, Production, Gross Margin, SWOT Analysis, Manufacturers, Market Strategy
erythropoietin, also known as EPO, hematopoietin, or hemopoietin, is a glycoprotein hormone did controls erythropoiesis, or red blood cell production. It is a cytokine (protein signaling molecule) for erythrocyte (red blood cell) precursors in the bone marrow. Human EPO has a molecular weight of 34 kDa.
Erythropoietin is produced by interstitial fibroblasts in the kidney in close association with peritubular capillary and proximal convoluted tubule. It is also produced in perisinusoidal cells in the liver. While liver production is predominant in the fetal and perinatal period, renal production is predominant during adulthood.
ReadComplete Report @ http://www.fiormarkets.com/report/global-erythropoietin-epo-market-outlook-2016-2021-19781.html
Exogenous erythropoietin can be provided to people Whose kidneys can not make enough. Recombinant human erythropoietin (rhEPO) is produced by recombinant DNA technology in cell culture. Several different pharmaceutical agents are available with a variety of glycosylation patterns and are collectively called erythropoiesis-stimulating agents (ESA). Major examples are epoetin alfa and epoetin beta. The following is a list of the most commonly used medicines for use in the treatment of anemia. Boxed warnings include a risk of death, myocardial infarction, stroke, venous thromboembolism, and tumor recurrence. RhEPO has been used as a performance-enhancing drug; It can often be detected in blood, due to slight differences from the endogenous protein, for example, in features of posttranslational modification.
This report provides detailed analysis of global markets for erythropoietin (EPO) from 2011-2015 and provides extensive market forecasts for 2016-2021 by region / country and subsectors. It covers the key technologies and market trends in the erythropoietin (EPO) market and further lays out an analysis of the factors influencing the supply / demand for erythropoietin (EPO), and the opportunities / challenges faced by industry participants. It also acts as an essential tool to companies.
Download Sample Report @ http://www.fiormarkets.com/report-detail/19781/request-sample
Global erythropoietin (EPO) Market Outlook 2016-2021, has been prepared based on the synthesis, analysis, and interpretation of Informationen über die Global Erythropoietin (EPO) market collected from specified sources. The report covers key technological developments in the recent times and profiles. The competitive landscape section of the report provides a clear insight into the market. The major players in the global erythropoietin (EPO) market are Amgen (USA), Johnson & Johnson (USA), Roche (Switzerland), Kyowa Hakko Kirin (Japan), 3SBIO (China) among others.
The report provides separate comprehensive analytics for the North America, Europe, Asia-Pacific, Middle East and Africa and Rest of World. In this sector, the global competitive landscape and supply / demand pattern of Erythropoietin (EPO) industry has been provided.
Contact us
Mark Stone
Sales Manager
Phone: (201) 465-4211
Email: sales@fiormarkets.com
Web: www.fiormarkets.com